Skip to main content
Premium Trial:

Request an Annual Quote

Twist Bioscience Prices $100M Stock Offering

NEW YORK – Twist Bioscience said on Thursday that it has priced a $100 million public stock offering at $33 per share.

The firm is offering approximately 3 million share of common stock. JP Morgan, Cowen and Company, and Evercore Group are acting as joint book-running managers and Robert W. Baird is acting as lead manager. Twist will grant the underwriters an option to purchase up to an additional 454,545 shares at the public offering price, less the underwriting discount and commissions.

In a statement, Twist said it intends to use the proceeds to invest in R&D and its commercial organization and global expansion, to expand production capacity, and for working capital and general corporate purposes. Twist added that it may use a portion of the proceeds "to in-license, acquire, or invest in complementary businesses or products."

In morning trading on the Nasdaq, shares of Twist were up 2 percent at $37.80.  

This is the latest in a series of stock offerings for Twist since its IPO in late 2018. The firm raised $84 million in May 2019 and $190 million in the quarter ended March 30 from sale of its stock.

Twist expects the offering to close on or about June 8.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.